Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors

Seminars in Liver Disease

Volumn 23, Issue 2, 2003, Pages 183-193

  Sulkowski, Mark S ^a,b  

^a Johns Hopkins Medical Institutions ^*  (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

HBV; HCV; Hepatotoxicity; HIV; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FATTY LIVER; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INCIDENCE; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SUPERINFECTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS B; HEPATITIS C; HIV PROTEASE INHIBITORS; HUMANS; LIVER;

EID: 0038621557     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39949     Document Type: Article

References (62)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860
2. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001;285:1308-1315
3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430
5. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-1327
6. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993;7:379-385
7. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet 1997;350:364
8. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-925
9. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80
10. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189
11. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902
12. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31
13. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999;13:F115-F121
14. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000;31:1234-1239
15. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000;44:3451-3455
16. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431
17. Monforte AA, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-123
18. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:316-318
19. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-1263
20. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-48
21. Crixivan® (indinavir sulfate) Package Insert. West Point, PA: Merck and Co., Inc.; 1999
22. Viracept® (nelfinavir mesylate) Package Insert. La Jolla, CA: Agouron Pharmaceuticals, Inc.; 2001
23. Agenerase® (amprenavir) Package Insert. Research Triangle Park, NC: GlaxoSmithKline, Inc.; 2002
24. Norvir® (ritonavir capsules) Package Insert. North Chicago, IL: Abbott Laboratories; 2001
25. Fortavase® (saquinavir soft gelatin capsule) Package Insert. Nutley, NJ: Roche Laboratories Inc.; 2002
26. Kaletra™ (lopinavir/ritonavir) Package Insert. North Chicago, IL: Abbott Laboratories; 2002
27. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-1292
28. Veronese L, Rautaureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000;44:821-826
29. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-113
30. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046
31. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998;42:3218-3224
32. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002;36: 283-294
33. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story. Arch Intern Med 1997;157:2129-2136
34. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experieinces. Rockville, MD: Division of AIDS. National Institute of Allergy and Infectious Diseases; 1996
35. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276
36. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-12676
37. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998;12:1722-1724
38. Masur Pb PH, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-478
39. Sulkowski MS, Thomas DL. Hepatitis C in the HIV infected patient. Ann Intern Med 2002;138:197-207
40. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-148
41. Velasco M, Moran A, Tellez MJ, Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999;340:1765-1766 (Letter)
42. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035
43. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-178
44. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10
45. Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in coinfected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS 2000;14:1111-1116
46. Jeffers LJ, Coelho-Little ME, Cheinquer H, et al. Procollagen-III peptide and chronic viral C hepatitis. Am J Gastroenterol 1995;90:1437-1440
47. Feinman SV, Berris B, Sinclair JC. E antigen and anti-e in HBsAg carriers. Lancet 1975;11:1173-1174
48. Vora S, Michon C, Junet C, et al. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests. AIDS 2000;14:2795-2797
49. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-117
50. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276:37514-37519
51. Benhamou Y, Di M, V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-287
52. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998;12:2289-2293
53. Gonzalez DR, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002;16:290-291
54. Poles MA, Dieterich DT, Schwarz ED, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:170-177
55. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-1848
56. Kessler HA, Johnson J, Follansbee S, et al. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:535-542
57. Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS 2001;15:289
58. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-1115
59. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-2730
60. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-1436
61. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192-196
62. Torre D, Tambini R, Cadario F, et al. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001;3:1579-1585